SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells

Journal of Hepatology

Volumn 41, Issue 2, 2004, Pages 267-273

  Wang, Si Y ^a,b   Chen, Bing ^a,b   Zhan, Yi Q ^a   Xu, Wang X ^a   Li, Chang Y ^a   Yang, Ri F ^c   Zheng, Hong ^a,b   Yue, Pei B ^a   Larsen, Steven H ^d   Sun, Hui B ^d   Yang, Xiaoming ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b Dept Pathophysiology Anhui Med U ^*  (China)

^c BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

c Met, hepatocyte growth factor receptor; ERK, extracellular signal regulated kinase; HGF c Met; HGF SF, hepatocyte growth factor scatter factor; Invasiveness; MDCK, Madin Darby canine kidney cells; SU5416; VEGF, vascular endothelial growth factor

Indexed keywords

MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; SEMAXANIB; THYMIDINE; TRITIUM; TYROSINE;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CELL CULTURE; CELL MOTILITY; CELL PROLIFERATION; CELL STIMULATION; CELL STRAIN 3T3; CELL STRAIN HEPG2; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; EMBRYO; ENZYME PHOSPHORYLATION; FILTER; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; WESTERN BLOTTING;

3T3 CELLS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; GENE EXPRESSION; HEPATOCYTE GROWTH FACTOR; HEPATOCYTES; HUMANS; INDOLES; LIVER NEOPLASMS; MICE; NEOPLASM INVASIVENESS; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; PYRROLES; TYROSINE;

EID: 4444363661     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2004.04.013     Document Type: Article

References (37)

1. Trusolino L., Comoglio P.M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer. 13:2002;289-300
2. Al-Obeidi F.A., Lam K.S. Development of inhibitors for protein tyrosine kinases. Oncogene. 19:2000;5690-5701
3. Uehara Y., Minowa O., Mori C., Shiota K., Kuno J., Noda T., et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature. 373:1995;702-705
4. Takayama H., LaRochelle W.J., Sharp R., Otsuka T., Kriebel P., Anver M., et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA. 94:1997;701-706
5. Weidner K.M., Sachs M., Birchmeier W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol. 121:1993;145-154
6. Ferracini R., Olivero M., Di Renzo M.F., Martano M., De Giovanni C., Nanni P., et al. Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene. 12:1996;1697-1705
7. Qian C.N., Guo X., Cao B., Kort E.J., Lee C.C., Chen J., et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res. 62:2002;589-596
8. Jeffers M., Fiscella M., Webb C.P., Anver M., Koochekpour S., Vande Woude G.F. The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci USA. 95:1998;14417-14422
9. Jeffers M., Schmidt L., Nakaigawa N., Webb C.P., Weirich G., Kishida T., et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA. 94:1997;11445-11450
10. Trusolino L., Bertotti A., Comoglio P.M. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell. 107:2001;643-654
11. Tavian D., De P.G., Benetti A., Portolani N., Giulini S.M., Barlati S. u-PA, c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int J Cancer. 87:2000;644-649
12. Firon M., Shaharabany M., Altstock R.T., Horev J., Abramovici A., Resau J.H., et al. Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells. Oncogene. 19:2000;2386-2397
13. Furge K.A., Kiewlich D., Le P. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci USA. 98:2001;10722-10727
14. Rosen E.M., Lamszus K., Laterra J., Polverini P.J., Rubin J.S., Goldberg I.D. HGF/SF in angiogenesis. Ciba Found Symp. 212:1997;215-226
15. Tomioka D., Maehara N., Kuba K., Mizumoto K., Tanaka M., Matsumoto K., et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res. 61:2001;7518-7524
16. Morotti A., Mila S., Accornero P., Tagliabue E., Ponzetto C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene. 21:2002;4885-4893
17. Angelov L., Salhia B., Roncari L., McMahon G., Guha A. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res. 59:1999;5536-5541
18. Yee K.W., O'Farrell A.M., Smolich B.D., Cherrington J.M., McMahon G., Wait C.L., et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood. 100:2002;2941-2949
19. DePrimo S.E., Wong L.M., Khatry D.B., Nicholas S.L., Manning W.C., Smolich B.D., et al. Expression profiling of blood samples from an SU5416 phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification. BioMed Central Cancer. 3:2003;3-14
20. Giles F.J., Cooper M.A., Silverman L., Karp J.E., Lancet J.E., Zangari M., et al. Phase II study of SU5416 - a small molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor - in patients with refractory myeloproliferative disease. Cancer. 97:2003;1920-1928
21. Sun L., Tran N., Tang F., App H., Hirth P., McMahon G., et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem. 41:1998;2588-2603
22. Seglen P.O. Preparation of isolated rat liver cells. Methods Cell Biol. 13:1996;29-83
23. Date K., Matsumoto K., Kuba K., Shimura H., Tanaka M., Nakamura T. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene. 17:1998;3045-3054
24. Lai J.F., Kao S.C., Jiang S.T., Tang M.J., Chan P.C., Chen H.C. Involvement of focal adhesion kinase in hepatocyte growth factor-induced scatter of Madin-Darby canine kidney cells. J Biol Chem. 275:2000;7474-7480
25. Jiang Y., Xu W., Lu J., He F., Yang X. Invasiveness of hepatocellular carcinoma cell lines: contribution of hepatocyte growth factor, c-met, and transcription factor Ets-1. Biochem Biophys Res Commun. 286:2001;1123-1130
26. Gonzatti-Haces M., Seth A., Park M., Copeland T., Oroszlan S., Vande Woude G.F. Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. Proc Natl Acad Sci USA. 85:1988;21-25
27. Kuba K., Matsumoto K., Ohnishi K., Shiratsuchi T., Tanaka M., Nakamura T. Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells. Biochem Biophys Res Commun. 279:2000;846-852
28. Christensen J.G., Schreck R., Burrows J., Kuruganti P., Chan E., Chen J., et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 63:2003;7345-7355
29. Dong G., Chen Z., Li Z.Y., Yeh N.T., Bancroft C.C., Van Waes C. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res. 61:2001;5911-5918
30. Sipeki S., Bander E., Buday L., Farkas G., Bacsy E., Ways D.K., Farrago A. Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering. Cell Signal. 11:1999;885-890
31. Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., Yeh B.K., et al. Structure of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 276:1997;955-960
32. Kasahara Y., Tuder R.M., Taraseviciene-Stewart L., Le Cras T.D., Abman S., Hirth P.K., et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 106:2000;1311-1319
33. Smolich B.D., Yuen H.A., West K.A., Giles M.A., Albitar M., Cherrington J.M. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood. 97:2001;1413-1421
34. Fong T.A., Shawver L.K., Sun L., Tang C., App H., Powell T.J., et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:1999;99-106
35. Schiering N., Knapp S., Marconi M., Flocco M.M., Cui J., Perego R., et al. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proc Natl Acad Sci USA. 100:2003;12654-12659
36. Sattler M., Pride Y.B., Ma P., Gramlich J.L., Chu S.C., Quinnan L.A., et al. A novel small molecule met inhibitor induces apoptosis cells transformed by the oncigenic TPR-MET tyrosine kinase. Cancer Res. 63:2003;5462-5469
37. Itokawa T., Nokihara H., Nishioka Y., Sone S., Iwamoto Y., Yamada Y., et al. Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. Mol Cancer Ther. 1:2002;295-302